JP2010534627A5 - - Google Patents

Download PDF

Info

Publication number
JP2010534627A5
JP2010534627A5 JP2010517324A JP2010517324A JP2010534627A5 JP 2010534627 A5 JP2010534627 A5 JP 2010534627A5 JP 2010517324 A JP2010517324 A JP 2010517324A JP 2010517324 A JP2010517324 A JP 2010517324A JP 2010534627 A5 JP2010534627 A5 JP 2010534627A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
seq
peptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010517324A
Other languages
English (en)
Japanese (ja)
Other versions
JP5352586B2 (ja
JP2010534627A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/006152 external-priority patent/WO2009015841A1/en
Publication of JP2010534627A publication Critical patent/JP2010534627A/ja
Publication of JP2010534627A5 publication Critical patent/JP2010534627A5/ja
Application granted granted Critical
Publication of JP5352586B2 publication Critical patent/JP5352586B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010517324A 2007-07-27 2008-07-25 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物 Expired - Fee Related JP5352586B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP07014796 2007-07-27
EP07014796.2 2007-07-27
US95310907P 2007-07-31 2007-07-31
US60/953,109 2007-07-31
US98124107P 2007-10-19 2007-10-19
US60/981,241 2007-10-19
PCT/EP2008/006152 WO2009015841A1 (en) 2007-07-27 2008-07-25 Composition of tumour-associated peptides and related anti-cancer vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013061688A Division JP5746251B2 (ja) 2007-07-27 2013-03-25 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物

Publications (3)

Publication Number Publication Date
JP2010534627A JP2010534627A (ja) 2010-11-11
JP2010534627A5 true JP2010534627A5 (https=) 2011-11-17
JP5352586B2 JP5352586B2 (ja) 2013-11-27

Family

ID=39926464

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010517324A Expired - Fee Related JP5352586B2 (ja) 2007-07-27 2008-07-25 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物
JP2013061688A Expired - Fee Related JP5746251B2 (ja) 2007-07-27 2013-03-25 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013061688A Expired - Fee Related JP5746251B2 (ja) 2007-07-27 2013-03-25 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物

Country Status (20)

Country Link
US (1) US7994276B2 (https=)
EP (2) EP2178557B1 (https=)
JP (2) JP5352586B2 (https=)
KR (1) KR101167392B1 (https=)
CN (2) CN103360466B (https=)
AU (1) AU2008281013B2 (https=)
BR (1) BRPI0814140A2 (https=)
CA (2) CA2694771A1 (https=)
DK (1) DK2567707T3 (https=)
EA (2) EA023928B1 (https=)
ES (1) ES2608583T3 (https=)
HU (1) HUE032379T2 (https=)
LT (1) LT2567707T (https=)
MX (1) MX2010001088A (https=)
NZ (1) NZ582823A (https=)
PL (1) PL2567707T3 (https=)
PT (1) PT2567707T (https=)
SI (1) SI2567707T1 (https=)
UA (2) UA103882C2 (https=)
WO (1) WO2009015841A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
HUE032379T2 (en) * 2007-07-27 2017-09-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
ES2532896T5 (es) * 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201019331D0 (en) * 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
CN104066746B (zh) * 2011-10-28 2017-12-05 肿瘤疗法科学股份有限公司 Topk肽及包含它们的疫苗
CN104428411B (zh) * 2012-05-08 2018-11-23 健康科学西部大学 用于cd4+t细胞群之抗原特异性扩增的标准化离体平台
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
TWI636065B (zh) * 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物
US11203783B2 (en) 2013-11-21 2021-12-21 Repertoire Genesis Incorporation T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
CN107406857B (zh) 2015-01-09 2021-06-29 埃图比克斯公司 用于联合免疫治疗的方法和组合物
CN104630145A (zh) * 2015-01-12 2015-05-20 杨世成 一种抗肿瘤t细胞、其制备方法和抗肿瘤药物
GB201505585D0 (en) * 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
TWI772927B (zh) * 2015-03-31 2022-08-01 德商英麥提克生物技術股份有限公司 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架
US11149087B2 (en) * 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
CN104926944B (zh) * 2015-05-22 2018-04-13 北京康爱瑞浩生物科技股份有限公司空港分公司 多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
MA54884A (fr) 2015-07-01 2022-01-12 Immatics Biotechnologies Gmbh Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen ovarialkarzinom und andere karzinome
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201512703D0 (en) 2015-07-20 2015-08-26 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
CN105586312A (zh) * 2016-02-29 2016-05-18 时宏珍 Hla-a0201限制性抗muc-1抗原特异性ctl的制备方法
CA3038089A1 (en) * 2016-09-27 2018-04-05 Selecta Biosciences, Inc. Recombinant immunotoxins for use in the treatment of cancer
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
ES2963635T3 (es) * 2017-03-28 2024-04-01 Ohio State Innovation Foundation Vacunas de péptido PD1 humano y usos de las mismas
SG11201909058WA (en) * 2017-04-10 2019-10-30 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
BR112019020959A2 (pt) * 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
GB201810358D0 (en) * 2018-06-25 2018-08-08 Univ College Cardiff Consultants Ltd Cancer-specific t-cell receptors
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
KR20220087431A (ko) * 2019-07-30 2022-06-24 유니버시티 헬스 네트워크 T 세포 수용체 및 이의 사용 방법
WO2021123232A1 (en) * 2019-12-18 2021-06-24 Evaxion Biotech Aps Nucleic acid vaccination using neo-epitope encoding constructs
CN111363009B (zh) * 2020-03-18 2020-10-30 北京鼎成肽源生物技术有限公司 一种直肠癌靶标抗原及其刺激培养的ctl细胞及其应用
CN111617238B (zh) * 2020-06-02 2022-12-13 苏州药明康德新药开发有限公司 小鼠ct26结直肠癌治疗性肿瘤多肽疫苗制剂及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
JPH02107189A (ja) * 1988-05-25 1990-04-19 City Of Hope 癌胎児抗原フラグメント
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1017810B1 (en) 1997-10-10 2004-05-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Agonist and antagonist peptides of carcinoembryonic antigen (cea)
US6756038B1 (en) * 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
US6623923B1 (en) 1998-12-23 2003-09-23 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
CA2384713A1 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
EP1287029A2 (en) * 2000-06-09 2003-03-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030017167A1 (en) 2000-06-09 2003-01-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20020102544A1 (en) 2000-09-15 2002-08-01 David Mack Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
CA2431313A1 (en) * 2000-12-08 2002-08-01 Eos Biotechnology, Inc. Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
AU2002330039A1 (en) * 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
JP2005536987A (ja) * 2002-04-01 2005-12-08 ユーロ−セルティーク エス.エイ. 抗原提示細胞標的化機構を含むエピトープ構築物
US20030211477A1 (en) * 2002-04-05 2003-11-13 Holmes Kathryn V. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
WO2004014867A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
DE602004015064D1 (de) * 2003-01-06 2008-08-28 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
NZ543922A (en) * 2003-05-05 2008-05-30 Angeletti P Ist Richerche Bio Synthetic gene encoding human carcinoembryonic antigen and uses thereof
CN1727362B (zh) * 2004-07-30 2010-12-01 中国人民解放军第二军医大学 癌胚抗原阳性肿瘤治疗性疫苗的制备及应用
WO2006027693A2 (en) 2004-09-09 2006-03-16 Exonhit Therapeutics Sa Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
EP1642905B1 (en) 2004-10-02 2009-01-21 Immatics Biotechnologies GmbH Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
ITRM20050064A1 (it) * 2005-02-16 2006-08-17 Univ Siena Peptide poliepitopico derivato dalla timidilato sintetasi avente attivita' immunologica e antitumorale e composizioni farmaceutiche relative.
ES2367643T3 (es) * 2005-04-26 2011-11-07 Immatics Biotechnologies Gmbh Identificador de un epítopo de linfocitos t presentado por el antígeno hla-a2 y derivado de la proteína del receptor de laminina inmadura del antígeno oncofetal y usos de este.
EP1760089B1 (en) 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
SI1806358T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
WO2008029271A2 (en) * 2006-02-27 2008-03-13 Gal Markel Ceacam based antibacterial agents
HUE032379T2 (en) * 2007-07-27 2017-09-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
WO2009117656A2 (en) * 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
ES2532896T5 (es) * 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan

Similar Documents

Publication Publication Date Title
JP2010534627A5 (https=)
JP2013522276A5 (https=)
JP2018521028A5 (https=)
Weinberger et al. Vaccines for the elderly
JP2013530157A5 (https=)
HRP20170115T1 (hr) Sastav tumoru-pridruženih peptida i povezanog cjepiva protiv karcinoma za liječenje glioblastoma (gbm-a) i drugih karcinoma
US11571472B2 (en) Immunogenic combinations
RU2017145963A (ru) Составы вакцин против неоплазии и способы их получения
JP6032853B2 (ja) 前立腺関連抗原分子由来hla結合ペプチドおよびその使用方法
JP2014534202A5 (https=)
JP2013536240A5 (https=)
JP2014521687A5 (https=)
JP2021527426A5 (https=)
JP2016518355A5 (https=)
EP3456339A3 (en) Novel immunotherapy against several tumors, such as lung cancer including nsclc
JP2007508272A5 (https=)
RU2014112002A (ru) Антигенные тау-пептиды и их применения
EA202091233A2 (ru) Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка
HRP20110965T1 (hr) Nove formulacije peptida povezanih s tumorima koji se vežu za molekule ljudskog leukocitnog antigena (hla) klase i ili ii za cjepiva
ES2993567T3 (en) Peptides and combinations of peptides for use in immunotherapy against an infection by sars-cov-2 (covid-19)
Del Giudice et al. Vaccines for the elderly
JP2015533376A5 (https=)
JP2018532782A5 (https=)
RU2018120009A (ru) Способ вакцинации против аутоантигена у пациента-человека
JP2014508734A5 (https=)